BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 36499340)

  • 1. B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.
    Chen X; Li J; Chen Y; Que Z; Du J; Zhang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
    Chen X; Zhang Y; Mo S; Ma H; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Apr; 147(4):465-473. PubMed ID: 35862858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
    Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
    Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
    Chen X; Ma H; Mo S; Zhang Y; Lu Z; Yu S; Chen J
    Front Immunol; 2022; 13():942154. PubMed ID: 35936015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma.
    Loch FN; Kamphues C; Beyer K; Schineis C; Rayya W; Lauscher JC; Horst D; Dragomir MP; Schallenberg S
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
    Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
    Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
    Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
    Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Prognostic Value of B7 Family Immune Checkpoints in Pancreatic Neuroendocrine Tumors.
    Mo S; Zong L; Chen X; Ban X; Li M; Lu Z; Yu S; Chen J
    Arch Pathol Lab Med; 2023 Feb; 147(2):193-201. PubMed ID: 35671167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
    Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy.
    Zhang Z; Cheng L; Li J; Qiao Q; Karki A; Allison DB; Shaker N; Li K; Utturkar SM; Atallah Lanman NM; Rao X; Rychahou P; He D; Konieczny SF; Wang C; Shao Q; Evers BM; Liu X
    Cancer Res; 2022 Oct; 82(19):3532-3548. PubMed ID: 35950917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
    Long L; Zhang L; Yang Y; Zhou Y; Chen H
    Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
    Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
    Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.